Glecaprevir and Pibrentasvir tablet （Mavyret）格卡瑞韦/哌仑他韦（艾诺全）

‌Glecaprevir-pibrentasvir‌ is a direct antiviral (DAA) combination for the treatment of chronic hepatitis C. It consists of two ingredients: ‌glecaprevir‌ (NS3/4A protease inhibitor) and ‌pibrentasvir‌ (NS5A inhibitor). The drug inhibits viral proliferation by targeting key links in viral replication, has a high cure rate and a broad-spectrum antiviral activity, and is suitable for most patients infected with hepatitis C virus (HCV) genotypes.

Indications and Mechanism of Action
‌Indications‌: For the treatment of chronic hepatitis C in adults, covering HCV genotypes 1-6, especially for patients without cirrhosis or with compensated cirrhosis.
‌Mechanism of Action‌:
Glecaprevir blocks the processing of viral polyproteins by inhibiting viral NS3/4A protease;
Pibrentasvir interferes with viral RNA replication and particle assembly by binding to NS5A protein.
The combination of the two can synergistically inhibit viral replication and reduce the risk of drug resistance.
Usage and precautions
‌Usage‌: Usually taken orally once a day, it needs to be taken with meals to improve the absorption rate. The specific course of treatment is determined by the doctor according to the patient’s liver disease stage and genotype (usually 8-12 weeks).
‌Precautions‌: ‌Must strictly follow the doctor’s instructions‌, and do not adjust the dose or stop the drug on your own;
Not suitable for patients with decompensated cirrhosis or severe liver dysfunction;
Liver function, viral load and other indicators need to be monitored regularly during treatment.
Adverse reactions
‌Common reactions‌: Headache, fatigue, nausea, etc., usually mild and tolerable;
‌Serious reactions‌: Rare liver function abnormalities or allergic reactions, need to seek medical attention immediately.
Medication guidance
‌Contraindications‌: People who are allergic to drug ingredients, moderate to severe liver dysfunction;
‌Drug interactions‌: There may be interactions with certain statins, anti-epileptic drugs, etc., and the doctor needs to be informed of the drugs currently being used in advance;
‌Follow-up requirements‌: After the end of treatment, a reexamination is required to confirm viral clearance and long-term monitoring of liver health.
‌Tip‌: This drug is a prescription drug. It needs to be evaluated by a specialist before use, and a treatment plan should be formulated according to individual conditions. If you feel uncomfortable or have any questions, you should consult a doctor in time.